Share on StockTwits

Equities researchers at RBC Capital boosted their target price on shares of InterMune (NASDAQ:ITMN) from $44.00 to $74.00 in a research report issued on Friday. RBC Capital’s price objective would suggest a potential upside of 0.79% from the stock’s previous close.

Shares of InterMune (NASDAQ:ITMN) traded up 0.33% on Friday, hitting $73.45. The stock had a trading volume of 6,514,834 shares. InterMune has a 52 week low of $10.95 and a 52 week high of $73.44. The stock’s 50-day moving average is $49.2 and its 200-day moving average is $37.88. The company’s market cap is $7.930 billion.

InterMune (NASDAQ:ITMN) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.72) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.56) by $0.16. The company had revenue of $35.70 million for the quarter, compared to the consensus estimate of $33.96 million. During the same quarter last year, the company posted ($0.77) earnings per share. InterMune’s revenue was up 141.2% compared to the same quarter last year. Analysts expect that InterMune will post $-2.72 EPS for the current fiscal year.

A number of other firms have also recently commented on ITMN. Analysts at Cowen and Company initiated coverage on shares of InterMune in a research note on Thursday. They set a “market perform” rating and a $74.00 price target on the stock. Separately, analysts at JMP Securities downgraded shares of InterMune from an “outperform” rating to a “market perform” rating in a research note on Tuesday. Finally, analysts at JPMorgan Chase & Co. downgraded shares of InterMune from an “overweight” rating to a “neutral” rating in a research note on Tuesday. They now have a $74.00 price target on the stock. Eight investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. InterMune presently has a consensus rating of “Hold” and a consensus target price of $63.08.

InterMune, Inc (NASDAQ:ITMN) is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.